Title
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
Date Issued
01 March 2022
Access level
metadata only access
Resource Type
letter
Author(s)
Publisher(s)
Elsevier Ltd
Start page
e100
Volume
23
Issue
3
Language
English
OCDE Knowledge area
Otras ciencias médicas
Oncología
Scopus EID
2-s2.0-85125308371
PubMed ID
Source
The Lancet Oncology
ISSN of the container
14702045
Sources of information:
Directorio de Producción Científica
Scopus